Der Report
Verifizierte Nachrichten zu Finanzierung, Hauptsitzen und Führungskräften der innovativsten Unternehmen der Welt
194 Berichte und es werden mehr
CytoDyn Appoints Robert E. Hoffman Chief Executive Officer
CytoDyn appointed Robert E. Hoffman, who joined as its CFO in May 2025, as CEO, succeeding Dr. Jacob Lalezari, with a focus on clinical execution and financial discipline.
Verastem Oncology Appoints Michael P. Bailey President and CEO
Verastem Oncology appointed director Michael P. Bailey, who spent 16 years at AVEO Pharmaceuticals, as President and CEO effective January 1, 2027, succeeding retiring CEO Daniel Paterson.
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
The Emmes Group Appoints Rama Kondru Chief Executive Officer
The Emmes Group’s Board appointed Rama Kondru, most recently CEO of its Veridix AI, technology, and data sciences business, as Chief Executive Officer.
Collegium Pharmaceutical Plans Headquarters Move to Downtown Boston
Collegium Pharmaceutical plans to move its corporate headquarters from Stoughton to One Lincoln in downtown Boston during the first quarter of 2027.
Smardt Names Sandeep Nair Chief Executive Officer
Smardt named Sandeep Nair Chief Executive Officer, succeeding Albert Yam, who transitions to Executive Director on the Board.
Apnimed Appoints Kevin R. Lind Chief Executive Officer
Apnimed appointed Board Chair Kevin R. Lind as CEO, succeeding founder Lawrence G. Miller, who will become Vice Chair, as the company builds capabilities toward a potential commercialization of AD109.
9 Berichte angezeigt • Seite 1 • Kategorie: all
Bleiben Sie dem Markt voraus
Erhalten Sie wöchentliche Insights direkt in Ihren Posteingang. Kein Spam, nur Intelligence.